{Reference Type}: Journal Article
{Title}: The Pediatric and Young Adult Choroidal and Ciliary Body Melanoma Genetic Study, A Survey by the European Ophthalmic Oncology Group.
{Author}: van Poppelen NM;Cassoux N;Turunen JA;Naus NC;Verdijk RM;Vaarwater J;Cohen V;Papastefanou VP;Kiratli H;Saakyan SV;Tsygankov AY;Rospond-Kubiak I;Mudhar HS;Salvi SM;Kiilgaard JF;Heegaard S;Moulin AP;Saornil MA;Garciá-Alvarez C;Fili M;Eide NA;Meyer P;Kivelä TT;de Klein A;Kilic E;Al-Jamal RT;
{Journal}: Invest Ophthalmol Vis Sci
{Volume}: 65
{Issue}: 4
{Year}: 2024 Apr 1
{Factor}: 4.925
{DOI}: 10.1167/iovs.65.4.12
{Abstract}: UNASSIGNED: To explore the genetic background of choroidal and ciliary body melanoma among children and young adults, with special focus on BAP1 germline variants in this age group.
UNASSIGNED: Patients under the age of 25 and with confirmed choroidal or ciliary body melanoma were included in this retrospective, multicenter observational study. Nuclear BAP1 immunopositivity was used to evaluate the presence of functional BAP1 in the tumor. Next-generation sequencing using Ion Torrent platform was used to determine pathogenic variants of BAP1, EIF1AX, SF3B1, GNAQ and GNA11 and chromosome 3 status in the tumor or in DNA extracted from blood or saliva. Survival was analyzed using Kaplan-Meier estimates.
UNASSIGNED: The mean age at diagnosis was 17 years (range 5.0-24.8). A germline BAP1 pathogenic variant was identified in an 18-year-old patient, and a somatic variant, based mainly on immunohistochemistry, in 13 (42%) of 31 available specimens. One tumor had a somatic SF3B1 pathogenic variant. Disomy 3 and the absence of a BAP1 pathogenic variant in the tumor predicted the longest metastasis-free survival. Males showed longer metastasis-free survival than females (P = 0.018).
UNASSIGNED: We did not find a stronger-than-average BAP1 germline predisposition for choroidal and ciliary body melanoma among children and young adults compared to adults. Males had a more favorable survival and disomy 3, and the absence of a BAP1 mutation in the tumor tissue predicted the most favorable metastasis-free survival. A BAP1 germline pathogenic variant was identified in one patient (1%), and a somatic variant based mainly on immunohistochemistry in 13 (42%).